ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer
Colombo, Nicoletta; Coleman, Robert L.; Wu, Xiaohua; Kose, Fatih; Wenham, Robert Michael; Sebastianelli, Alexandra; Hasegawa, Kosei; Zsiros, Emese; Rouge, Thibault De la Motte; Bidzinski, Mariusz; McNeish, Iain A.; Sehouli, Jalid; Korach, Jacob; Debruyne, Philip R.; Kim, Jae-Weon; De Melo, Andrea C.; Peng, Xuan; Bogusz, Agata M.; Yamada, Karin Sayuri; Monk, Bradley J. (2022)